Sparian Biosciences is a clinical stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. As neurologists and neuroscientists, co-founders Jeff Reich, MD, and Gavril Pasternak, MD, PhD, set out to build a central nervous system-oriented company with truly innovative compounds that offer new approaches to address areas of high unmet medical need. Our initial focus is on pain and substance use disorders.
Currently, we have five assets addressing pain, the opioid crisis and stimulant use disorder. Our strategy has been to find novel compounds with validated preclinical data and promising translational value from highly recognized academic labs and take the compounds through early-stage drug development. The Sparian pipeline is derived from the Pasternak Lab at Memorial Sloan Kettering Cancer Center, Rutgers University Medical School, the USC Michelson Center for Convergent Bioscience, Washington University, and University of Florida.
Sparian Biosciences has forged a uniquely strong relationship with National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and has received four NIDA HEAL grants worth nearly $60 M. Sparian also has a research collaboration with the U.S. Army Institute of Surgical Research in the Department of Defense.
Sparian is based out of BioLabs@NYULangone in New York City, a national biotech incubator, and the Cambridge Innovation Center in Kendall Square, Cambridge, MA.
